Cuba's group of biotechnology and pharmaceutical enterprises. A 2023 report gave the national industry as responsible for 61% of the medicines on Cuba's basic list; the group lists cancer monoclonal antibodies and therapeutic vaccines among its main products, and has told parliament that missing raw materials cause most shortages.
BioCubaFarma's own description (July 2025) is of a business organisation that produces medicines, equipment and high-technology services for human health, for export and for food production, with 47 enterprises, 164 production lines, 21 science and technology units and 16,490 workers, 265 of them with doctorates. Among its main products it lists prophylactic vaccines and biopharmaceuticals for cancer such as monoclonal antibodies and therapeutic vaccines; it also makes generic medicines and systems for early diagnosis and prevention of malignant tumours. Its head office is at Avenida Independencia No. 8126, Boyeros, Havana.
Granma's report of a National Assembly session, republished by the Pinar del Río newspaper Guerrillero on 28 July 2023, said 251 medicines (40% of the basic list) were missing and described the national industry as responsible for 61% of the list. BioCubaFarma's president Eduardo Martínez Díaz told the session that missing raw materials and materials caused 94% of shortages. He gave as causes a lack of timely financing, problems paying suppliers because banks refused to work with Cuba, usual suppliers stopping because of the US economic embargo, and global shortages of some materials. Of 14 oncology products, five were affected at the end of June 2023: cisplatin, carboplatin, vinblastine, paclitaxel and zoledronic acid.
Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.
Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.
A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.
Vinblastine is the vinca alkaloid in ABVD, the standard Hodgkin lymphoma regimen, and was formerly in the cisplatin combinations that first cured testicular cancer.
Zoledronic acid (Zometa) is a fifteen-minute infusion given every few weeks or months to strengthen bone and prevent fractures, spinal cord compression and the need for radiotherapy in people with myeloma or cancer that has spread to bone; it also treats dangerously high calcium caused by cancer.
Shares Vinblastine, Cisplatin.
Shares Vinblastine, Cisplatin.
Shares Vinblastine, Paclitaxel / nab-paclitaxel.
Shares Vinblastine, Paclitaxel / nab-paclitaxel, Cisplatin.
Shares Vinblastine, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/